Myelin Oligodendrocyte Glycoprotein Fluorescence-Activated Cell Sorting (FACS) Assay
MOG, ADEM antibody, MOG-IgG, NMO antibody, Optic Neuritis Antibody, Transverse Myelitis Antibody, Vision Loss Antibody
Test Codes
EPIC: LAB8548, Beaker: XMOGFS, Mayo: MOGFS
Department
Send Outs
Instructions
Patient Preparation: For optimal antibody detection, we recommend drawing the specimen before initiation of immunosuppressant medication.
Specimen Collection Criteria
Collect: One plain Red-top tube.
Physician Office/Draw Specimen Preparation
Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).
Preparation for Courier Transport
Transport: 2.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 1.0 mL)
Rejection Criteria
- Grossly hemolyzed specimen
- Grossly icteric specimen
- Grossly lipemic specimen
- Specimens not collected and processed as indicated.
In-Lab Processing
Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).
Transport: 2.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 1.0 mL)
Storage
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): 72 hours
Refrigerated (2-8°C or 36-46°F): 28 days
Frozen (-20°C/-4°F or below): 28 days
Specimen Storage in Department Prior to Disposal:
Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.
Laboratory
Sent to Mayo Medical Laboratories, Rochester, MN.
Performed
Monday, Tuesday, Thursday.
Results available 5-8 days.
Reference Range
Negative.
Test Methodology
Flow Cytometry
Interpretation
A positive value for myelin oligodendrocyte glycoprotein (MOG)-IgG is consistent with an neuromyelitis optica (NMO)-like phenotype, and in the setting of acute disseminated encephalomyelitis (ADEM), optic neuritis and transverse myelitis indicates an autoimmune oligodendrogliopathy with potential for relapsing course. Identification of MOG-IgG allows distinction from MS and may justify initiation of appropriate immunosuppressive therapy (not MS disease-modifying agents) at the earliest possible time. This allows early initiation and maintenance of optimal therapy. Recommend follow-up in 3 to 6 months as persistence of MOG-IgG seropositivity predicts a relapsing course.
This autoantibody is not found in healthy subjects.
Clinical Utility
Diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis.
Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy.
Diagnosis of neuromyelitis optica (NMO).
Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease.
Diagnosis of ADEM.
Prediction of a relapsing disease course.
CPT Codes
86363
86363-titer (if appropriate)
Contacts
Send Outs Laboratory – RO
248-551-9045
Name: Send Outs Laboratory – RO
Location:
Phone: 248-551-9045
Last Updated
10/10/2023
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.